Connor, Clark & Lunn Investment Management Ltd. Blueprint Medicines Corp Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 142,717 shares of BPMC stock, worth $13.2 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
142,717
Previous 5,132
2680.92%
Holding current value
$13.2 Million
Previous $474,000
2525.95%
% of portfolio
0.06%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
380Shares Held
65.9MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$625 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$613 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$524 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$395 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$231 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.51B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...